RespireRx Pharmaceuticals (OTC:RSPI) Chief Financial Officer Jeff Margolis joins Natalie Stoberman from the Proactive studios to share the company's establishment of ResolutionRx in Australia, to which Margolis is now its Director.
ResolutionRx is a currently wholly-owned, unlisted public company in Australia, as the first in a series of steps that include, but are not limited to financings, research and clinical development, manufacturing, regulatory and compliance, all for the purpose of developing compounds that target the body’s endocannabinoid system.
Margolis says a few of the main purposes for the creation of ResolutionRx is to allow it to participate in the Australian research and development tax credit.